Eli Lilly and Co (BSP:LILY34)
R$ 130.52 -2.2 (-1.66%) Market Cap: 3.72 Til Enterprise Value: 3.84 Til PE Ratio: 113.84 PB Ratio: 56.38 GF Score: 73/100

Eli Lilly and Co at Credit Suisse Healthcare Conference - Scottsdale Transcript

Nov 13, 2019 / 03:35PM GMT
Release Date Price: R$15.47
Evan David Seigerman;dit Suisse AG
CrÃ;Research Division - VP & Senior Equity Research Analyst

© -

Excellent. Hi, there. My name is Evan Seigerman. I'm the senior large-cap biotechnology analyst here at Crédit Suisse. And I also have my colleague, Matt Weston, from the European pharma team.

Matthew Weston;dit Suisse AG
CrÃ;Research Division - MD and Co-Head of European Pharmaceutical Equity Research

© -

Good morning, everybody.

Evan David Seigerman;dit Suisse AG
CrÃ;Research Division - VP & Senior Equity Research Analyst

© -

And it is my pleasure to have Eli Lilly with us today. And from Eli Lilly, we have Anne White, SVP and President of Lilly Oncology; Maura Dickler, VP, Oncology Late-Phase Development; and Kim Blackwell, VP, Early-Phase Clinical Development. Thank you for coming to Scottsdale.

Anne E. White
Eli Lilly and Company - Senior VP & President of Lilly Oncology

It's our

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot